Rescue of CFTR function impaired by mutations in exon 15 Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020
Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections Year: 2010
Rescue of mutant ABCA3 by small molecular correctors Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017
NIK-616,a new type of selective PDE IV inhibitor with reduced emetic activity Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002
A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations Source: Eur Respir J, 56 (5) 2000205; 10.1183/13993003.00205-2020 Year: 2020
Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-11a Source: Eur Respir J 2010; 36: 311 Year: 2010
CFTR dysfunction and its relationship to phenotype and development of new treatments restoring CFTR function Source: Annual Congress 2013 –PG20 Cystic fibrosis: an update of the basic defects and clinical problems in CF children and adults Year: 2013
CAM-kinase II inhibition and protein kinase C activation combine synergistically to initiate ciliary beat frequency despite cellular hypothermia Source: Eur Respir J 2002; 20: Suppl. 38, 88s Year: 2002
Dual aVß6/aVß1 inhibitor PLN-74809 blocks multiple TGF-ß activation pathways associated with IPF Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
A novel mechanism of autotaxin-mediated cell signaling that is independent of catalytic activity and inhibited by ziritaxestat Source: Virtual Congress 2021 – Pathogenic progress in airway diseases Year: 2021
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020
Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease Year: 2012
NIK-616, a new type of selective phosphodiesteraseIV(PDE IV) inhibitor with reduced emetic activity Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Regulation of γ-GCS gene expression by TGF-β in type II epithelial cells: role for Fra-1/AP-1/ARE Source: Eur Respir J 2002; 20: Suppl. 38, 96s Year: 2002
Regulation of the response to stop mutation read-through by the nonsense mediated decay mechanism Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007
Effect of in vivo blockade of the KCa3.1 ion channel on type II alveolar epithelial cell turnover in pulmonary fibrosis Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018
DTX3L mediated regulation of TBK1 positively regulates type I IFN signalingpathway and cellular antiviral response Source: Virtual Congress 2020 – Different aspects of paediatric viral and bacterial lung infections Year: 2020
BMP receptors in the lung - Characterization and identification of a novel BMPRIa isoform Source: Eur Respir J 2003; 22: Suppl. 45, 270s Year: 2003